0000899243-20-031557.txt : 20201118 0000899243-20-031557.hdr.sgml : 20201118 20201118194350 ACCESSION NUMBER: 0000899243-20-031557 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201116 FILED AS OF DATE: 20201118 DATE AS OF CHANGE: 20201118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HENDERSON MICHAEL THOMAS CENTRAL INDEX KEY: 0001779990 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38959 FILM NUMBER: 201326689 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BridgeBio Pharma, Inc. CENTRAL INDEX KEY: 0001743881 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: (650) 391-9740 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 FORMER COMPANY: FORMER CONFORMED NAME: BridgeBio Pharma LLC DATE OF NAME CHANGE: 20180618 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-16 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001779990 HENDERSON MICHAEL THOMAS C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET PALO ALTO CA 94301 0 1 0 0 Chief Business Officer Common Stock 2020-11-16 4 M 0 10000 1.05 A 277751 D Common Stock 2020-11-16 4 S 0 10000 45.00 D 267751 D Common Stock 2020-11-16 4 M 0 12813 A 280564 D Common Stock 2020-11-16 4 F 0 6353 44.33 D 274211 D Stock Option (Right to Buy) 1.05 2020-11-16 4 M 0 10000 0.00 D 2020-05-19 2029-09-24 Common Stock 10000 18282 D Restricted Stock Units 2020-11-16 4 M 0 12813 0.00 D Common Stock 12813 179375 D This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 12,813 shares of Common Stock underlying the Reporting Person's RSUs. The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. /s/ Tara Condon, Attorney-in-Fact 2020-11-18